A Phase 3, Randomized, Double-blind, Multicenter, Parallel-group, Placebo-controlled, Fixed-Dose Safety and Efficacy Study of SPD489 Compared With Placebo in Preschool Children Aged 4-5 Years With Attention-deficit/Hyperactivity Disorder
Latest Information Update: 20 May 2022
Price :
$35 *
At a glance
- Drugs Lisdexamfetamine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Therapeutic Use
- Sponsors Shire
- 12 May 2022 Results evaluating evaluate the acute efficacy, safety, and tolerability of lisdexamfetamine dimesylate (LDX) versus placebo (PBO) in preschool-aged children with attention-deficit/hyperactivity disorder (ADHD) published in the Journal of the American Academy of Child and Adolescent Psychiatry
- 25 Jan 2019 Status changed from recruiting to completed.
- 08 Sep 2017 Status changed from not yet recruiting to recruiting.